Trial Profile
Therapy discontinuations related to side effects with the use of antitumour necrosis factor treatments in patients with chronic rheumatic diseases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 26 Apr 2017 New trial record